Clinical trials: Influenza H1N1
Novel 2009 Influenza A (H1N1) Infection
H-IVIG Treatment for Severe H1N1 2009
Treatment with hyperimmune intravenous immunoglobulin (H-IVIG), derived from convalescent plasma from patients recovered from H1N1 2009 influenza A infection, for patients with severe H1N1 2009 infection will decrease mortality…
- Trial name
- NCT01617317
- Testing
- Hyperimmune intravenous immunoglobulin, Intravenous immunoglobulin
- Where
- Hong Kong
- Volunteers
- 34 people
- Sponsor
- The University of Hong Kong
Lymphoma, Multiple Myeloma
Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy
The purpose of this study is to determine whether adults with hematologic malignancies on active systemic therapy or shortly after bone marrow transplantation need one or two doses of adjuvanted vaccine to achieve best possible…
- Conditions
- Lymphoma, Multiple Myeloma, Influenza A Virus, H1N1 Subtype
- Trial name
- NCT01016548
- Testing
- AS03-adjuvanted H1N1 pandemic influenza vaccine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- University Health Network, Toronto
H1N1 Virus
A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza
At present influenza immunity can only be reliably confirmed by a blood test. This test is invasive for the patient. This study is intended to validate an oral fluid/saliva antibody test for the variant Swine Influenza H1N1.
- Trial name
- Snuffles (NCT01192958)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Public Health England
Virus Diseases, Respiratory Tract Diseases
Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients
The 2009 flu pandemic is a global outbreak of a new strain of influenza A virus subtype H1N1, commonly known as swine flu, that was first identified in April 2009.
- Conditions
- Virus Diseases, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
- Trial name
- NCT01055990
- Testing
- split-virion, non-adjuvanted H1N1 vaccine of 15 μg, blood fix
- Where
- China
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Shanghai Public Health Clinical Center
H1N1/2009 Influenza
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults
The purpose of this study is to assess the safety and effectiveness (immune response) to a licensed H1N12009 influenza vaccine in aboriginal children and adults.
- Trial name
- NCT01001026
- Testing
- Arepanrix
- Where
- 5 sites in Canada
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- David Scheifele
Influenza A H1N1
Study of SAB-176 in Healthy Adult Participants
Healthy adult participants will be challenged with the H1N1 Influenza virus and then treated with either SAB-176 or placebo.
- Trial name
- NCT04850898
- Testing
- SAB-176
- Where
- United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Novel 2009 Influenza H1N1
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children, adolescents, and adults.
- Trial name
- NCT00973700
- Testing
- MF59-eH1N1_f, eH1N1_f
- Where
- Costa Rica
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
HIV Infections, H1N1 Influenza Virus
Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth
Children and people infected with HIV are particularly susceptible to influenza infections. This study testED the safety and effectiveness of a vaccine for the new H1N1 influenza virus in children and youth infected with HIV.
- Trial name
- NCT00992836
- Testing
- Influenza A (H1N1) 2009 monovalent vaccine
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen
Haukeland University Hospital has approximately 8000 employees many of whom will be in the front line to receive the pandemic A/H1N1 vaccine. We propose to conduct a safety and immunogenicity study in these subjects
- Trial name
- H1N1VAC (NCT01003288)
- Testing
- Adjuvanted influenza H1N1split virion vaccine
- Where
- Norway
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- University of Bergen
Influenza
Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children
The purpose of this study is to compare the safety and effectiveness (immune response) to one or two doses of adjuvanted H1N12009 influenza vaccine in young children. An adjuvant is an additive that can boost the immune response.
- Trial name
- NCT01000831
- Testing
- adjuvanted Arepanrix
- Where
- 6 sites in Canada
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Influenza
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
A Phase 2 Randomized, Placebo- and Active-Controlled, Human Influenza A/California/04/2009 (H1N1) Challenge Study Following Administration of an Oral H1N1 Hemagglutinin (HA) Adenoviral-Vector Based Seasonal Influenza Vaccine and…
- Trial name
- NCT02918006
- Testing
- VXA-A1.1, Fluzone®
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Vaxart
H1N1 Flu
Study of the Safety and Immunogenicity of H1N1 Vaccine
The Purpose Of This Study Is To Assess The Safety, Immunogenicity, And Tolerability Of A H1N1 Vaccine In Healthy Adults
- Trial name
- NCT01177202
- Testing
- HAC1 Vaccine
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Fraunhofer, Center for Molecular Biotechnology
Influenza
Influenza A 2009 H1N1 Challenge Study in Healthy Adults
Background: A challenge study exposes a person to a disease and allows researchers to study the disease through the body's healing process.
- Trial name
- NCT01646138
- Testing
- Ca/04/2009/H1N1 Vero Grown Challenge Virus
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
A/H1N1 Influenza, Swine Flu
Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon
The pandemic A/H1N1 virus was named "swine flu" when the current outbreak started. Although it is not yet confirmed that the index case acquired the virus from pigs, the nomenclature "swine flu" was due to the fact that the virus…
- Trial name
- NCT01298206
- Where
- Lebanon
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Influenza
Follow-up of Immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers After 6 Months
In the spring of 2009, a recently emerged novel influenza A (H1N1) virus was first identified in Mexico and USA and it has continued to spread globally.
- Trial name
- NCT01096238
- Volunteers
- 185 people
- Sponsor
- National Taiwan University Hospital
Influenza A
Convalescent Plasma Treatment in Severe 2009 H1N1 Infection
Treatment of severe 2009 H1N1 infection with convalescent plasma will reduce mortality.
- Trial name
- NCT01306773
- Testing
- H1N1 convalescent plasma and oseltamivir, Oral Oseltamivir alone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The University of Hong Kong
Virus Diseases, Respiratory Tract Diseases
Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older
The primary safety objective of this study is to assess the safety of split- virion inactivated H1N1 vaccine with and without adjuvant when administered at the 7.5,15 or 30 mcg dose.
- Conditions
- Virus Diseases, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
- Trial name
- NCT00975572
- Testing
- split-virion, non-adjuvanted H1N1 vaccine of 30 μg, Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg, Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg
- Where
- China
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza, Pandemic Influenza
A/H1N1 Immunogenicity and Safety in Adults
The purpose of the study is to obtain immunogenicity and safety data at different dose levels of an investigational H1N1 pandemic influenza vaccine in healthy adults 18 years of age and older.
- Trial name
- NCT00959465
- Testing
- H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)
- Where
- 5 sites in Austria, Germany
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza, Influenza A
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
The goal of this clinical study is to prove the no less immunogenicity of the Grippol Quadrivalent vaccine compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three identical strains of the…
- Conditions
- Influenza, Influenza A, Influenza, Human, Influenza Type B
- Trial name
- NCT06385821
- Testing
- Grippol Quadrivalent, Grippol Plus
- Where
- 14 sites in Russia
- Volunteers
- 824 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Influenza
Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1
In agreement with the World Organization of the Health (WHO), during the annual epidemics of influenza they become infected between 10-20 % of the total population, appearing from a feverish disease up to leading to the…
- Trial name
- NCT00989274
- Testing
- Vaccine Sanofi A(H1N1) 15 ug & trivalent, Vaccine Sanofi (H1N1) 15 ug.nonadyuvante, Vaccine Sanofi A(H1N1) 7.5 ug
- Where
- Mexico
- Sponsor
- Instituto Nacional de Salud Publica, Mexico